UFT/leucovorin plus weekly paclitaxel in the treatment of solid tumors

The palliation of symptoms and improvement of quality of life are important aspects of therapy irt patients with incurable metastatic cancer. This art icle describes the preliminary results of a phase I study of uracil and teg afur, an orally available fluorouracil (5-FU) derivative combined with oral leucovorin plus weekly intravenous paclitaxel, While the daily oral dose o f UFT is fixed at 300 mg/m(2) plus 90 mg leucovorin on days 1 to 28, paclit axel is escalated in 10 mg/m(2) steps starting with 50 mg/m(2) weekly as a 1-hour infusion, To date, 26 patients with a median age of 57 years have be en entered into the protocol and have received a median 2.2 cycles of thera py. Dose level 4 (paclitaxel 80 mg/m(2)) has been recently completed. Major dose-limiting toxicities were fatigue syndrome (two patients) and diarrhea (five patients). Preliminary responses have been observed in three of 14 c urrently evaluable patients. This protocol is taking the development of pro tracted 5-FU administration-given orally as UFT-in combination with paclita xel one step further, using paclitaxel in a dose-dense, weekly schedule. It is hoped that art active regimen for the outpatient treatment of solid tum ors will be developed.